Challenger Limited (ASX:CGF)
Australia · Delayed Price · Currency is AUD 8.18
-0.05 (-0.61%)
Aug 1, 2025, 4:10 PM AEST
Verve Therapeutics Cash Flow Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2016 - 2020 |
Net Income | 145.8 | 129.9 | 171.4 | 253.7 | 592.3 | -416 | Upgrade |
Depreciation & Amortization | 18.5 | 13.1 | 11.8 | 11.3 | 10.8 | 12.3 | Upgrade |
Other Amortization | 0.7 | 0.7 | 2.7 | 2.7 | 4.5 | 3 | Upgrade |
Gain (Loss) on Sale of Investments | -508.2 | -415.9 | -343.1 | 1,544 | -570 | 866.6 | Upgrade |
Stock-Based Compensation | 19.7 | 19.6 | 16.8 | 13 | 11.5 | 14.2 | Upgrade |
Change in Accounts Receivable | -28.5 | -14.8 | 62.3 | 12.9 | 72.1 | 7.9 | Upgrade |
Change in Income Taxes | 22.1 | 22.1 | 98.3 | -170.1 | 147.9 | -198.6 | Upgrade |
Change in Insurance Reserves / Liabilities | 693.3 | 986.2 | 334.7 | -74.5 | 1,015 | -584.1 | Upgrade |
Change in Other Net Operating Assets | -245.9 | 98.6 | 912.5 | 889.2 | 1,220 | 483.7 | Upgrade |
Other Operating Activities | 0.8 | 4.4 | 8 | - | 73.7 | 290 | Upgrade |
Operating Cash Flow | 342 | 1,051 | 1,291 | 2,487 | 2,577 | 484.9 | Upgrade |
Operating Cash Flow Growth | -36.06% | -18.55% | -48.09% | -3.48% | 431.37% | -25.66% | Upgrade |
Capital Expenditures | -1 | -1.9 | -7.9 | -2.9 | -12.9 | -9.3 | Upgrade |
Cash Acquisitions | - | - | - | -28.9 | -2.5 | -10.2 | Upgrade |
Investment in Securities | -814.1 | -2,131 | -1,493 | -2,260 | -920.9 | -1,623 | Upgrade |
Investing Cash Flow | -643.4 | -1,944 | -1,338 | -2,123 | -831 | -1,478 | Upgrade |
Long-Term Debt Issued | - | 1,254 | 565.9 | - | 385 | 823.7 | Upgrade |
Total Debt Repaid | -10.6 | -9.8 | -467.8 | -484.3 | -1,768 | -5.1 | Upgrade |
Net Debt Issued (Repaid) | 499.1 | 1,244 | 98.1 | -484.3 | -1,383 | 818.6 | Upgrade |
Issuance of Common Stock | - | - | 15 | - | 35.7 | 275.3 | Upgrade |
Repurchases of Common Stock | -49.8 | -14.6 | -19 | -1.7 | - | - | Upgrade |
Common Dividends Paid | -179.2 | -149.4 | -122.5 | -133.7 | -64 | -216.4 | Upgrade |
Other Financing Activities | - | - | -6.6 | -0.1 | -6.9 | -14.2 | Upgrade |
Financing Cash Flow | 270.1 | 1,080 | -35 | -619.8 | -1,418 | 863.3 | Upgrade |
Miscellaneous Cash Flow Adjustments | -186.4 | -265.8 | -58.1 | - | - | - | Upgrade |
Net Cash Flow | -217.7 | -78.3 | -139.7 | -256.3 | 327.5 | -130 | Upgrade |
Free Cash Flow | 341 | 1,050 | 1,283 | 2,484 | 2,564 | 475.6 | Upgrade |
Free Cash Flow Growth | -35.51% | -18.20% | -48.35% | -3.11% | 439.05% | -19.72% | Upgrade |
Free Cash Flow Margin | 9.61% | 32.04% | 49.82% | - | 77.08% | 26.22% | Upgrade |
Free Cash Flow Per Share | 0.48 | 1.50 | 1.84 | 2.85 | 2.79 | 0.78 | Upgrade |
Cash Interest Paid | 334.3 | 295.7 | 180.1 | 53.8 | 56.1 | 104.6 | Upgrade |
Cash Income Tax Paid | - | 21.6 | 122.6 | 264.9 | 90.9 | 15.8 | Upgrade |
Levered Free Cash Flow | -190.66 | -1,117 | -1,397 | -1,834 | -1,679 | 1,888 | Upgrade |
Unlevered Free Cash Flow | 475.46 | -512.3 | -965.61 | -1,808 | -1,476 | 2,017 | Upgrade |
Change in Net Working Capital | 672.5 | 1,562 | 1,718 | 1,620 | 2,170 | -2,139 | Upgrade |
Source: S&P Global Market Intelligence. Insurance template. Financial Sources.